rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alzamend Neuro, Inc.

ALZN · Nasdaq

Health CareBiotechnologyNot moving yet

ALZN stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 3.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$660K
Insider sales, 12 months
$17K
Officials’ trades on record
0
Institutions holding
12 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$878K$0$603KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months4
Buyers · sellers1 · 3
WhoDidSharesTraded
Milton C. Ault IIIDirectorsold2,000at $1.5626 Aug 2026filed 31 Aug 2026
Milton C. Ault IIIDirectorbought108,388at $1.0014 Apr 2026filed 16 Apr 2026
Milton C. Ault IIIDirectorbought108,388at $1.0014 Apr 2026filed 31 Aug 2026
Milton C. Ault IIIDirectorbought2,000at $1.0314 Apr 2026filed 31 Aug 2026
Milton C. Ault IIIDirectorbought108,388at $1.0014 Apr 2026filed 31 Aug 2026
Milton C. Ault IIIDirectorbought2,000at $1.0314 Apr 2026filed 31 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders12-1 on the quarter
New · exited2 · 3
Reported value$3.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Kingsbury Capital Investment Advisors LLCadded · filed 25 Aug 20261,329,100$1.6M+762,367+134.5%
KMT WEALTH MANAGEMENT, LLCnew · filed 5 Aug 20261,329,100$1.6M+1,329,100
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202626,371$32K-19,309−42.3%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202621,020$25K00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,556$9,067+3,156+71.7%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 20263,517$4,220-2,667−43.1%
UBS Group AGreduced · filed 13 Aug 20262,352$2,822-2,152−47.8%
BlackRock, Inc.unchanged · filed 7 Aug 2026437$52400.0%
IFG Advisory, LLCnew · filed 14 Aug 202622$26+22
SBI Securities Co., Ltd.unchanged · filed 23 Jul 202622$2600.0%
30 Jun 2025 – 30 Jun 2026
71013Jun 25Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Milton C. Ault III Company insiderDirector · last 26 Aug 2026117 · 29
Ault Lending, Llc Company insiderDirector, Other · last 31 Jul 20260 · 0
Hyperscale Data, Inc. Company insiderDirector, Other · last 31 Jul 20260 · 0
David J. Katzoff Company insiderChief Financial Officer · last 17 Apr 20263 · 0
Henry Carl Nisser Company insiderEVP and General Counsel · last 17 Apr 20260 · 0
Jeffrey Oram Company insiderDirector · last 17 Apr 20260 · 0
Mark Gustafson Company insiderDirector · last 17 Apr 20260 · 2
Stephan Jackman Company insiderChief Executive Officer · last 17 Apr 20262 · 0
William B. Horne Company insiderDirector · last 17 Apr 20263 · 1
Lynne Fahey McGrath Company insiderDirector · last 23 Oct 20251 · 4
Andrew H. Woo Company insiderDirector · last 15 Mar 20220 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2026 · to 22 Jul 202612.6%
Cash and equivalentsFY 2026 · to 30 Apr 2026$711K

Analyst forecasts

No analyst forecasts yet.